Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
WuXi Biologics (Cayman) Inc (WXIBF) fair value: what the stock is really worth
As of Sep 28, 2026: fair value of WuXi Biologics (Cayman) Inc $7.45, price $6.77, upside +10.0%, quality 68 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
WB
Some data
Oct 3, 2026
Some data
Oct 3, 2026
WuXi Biologics (Cayman) Inc
WXIBF · USNeutralQuality growthThe stock looks roughly fairly valued with average quality.
·Fair value $7.45 · Fairly valued (+10.0%)
✓Quality 68/100
✓Healthy Growth (revenue 5y +30.5 %/yr)
✓Highly profitable · 22.5% net margin (TTM)
✓Low debt · generates free cash flow
✓Wide moat 71/100
!Evidence only medium, so the estimate is less certain
Watch WuXi Biologics (Cayman) Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range $1.30 – $34.25 · fair‑value band $4.88 – $13.75 · the $6.77 price screens below the $7.45 fair value. Dashed = 300-day average. As of Oct 3, 2026.
Company profile
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC.
Show more
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Tumor Associated Antigens ("TAA") mAb Technology, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; research and development in relation to biologics; international sales contracting service; vaccine contract development and manufacturing organization (CDMO) and related business; development, production, and distribution of biotechnological products; and engages in investment and material supplier activities. WuXi Biologics (Cayman) Inc. was incorporated in 2014 and is headquartered in Wuxi, China.
Stock analysis
WuXi Biologics (Cayman) Inc (WXIBF) currently trades at $6.77, while our model-based Fair Value estimate is $7.45, implying the stock looks roughly 9.1% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $8.07 per share, and 2 of the 24 models we run sit above the $6.77 price.
Bear case: the Asset-Based group reads lowest at $1.15, and 22 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: $4.88 (bear) to $13.75 (bull), the price of $6.77 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
WuXi Biologics (Cayman) Inc reported revenue of 21.2B CNY in FY2025 versus 10.3B CNY in FY2021, a compound +19.8%/yr. Reported net income was 4.8B CNY in FY2025, compounding +9.0%/yr from FY2021.
Key figures
Market cap $28.3B · P/E ratio 39.8 · P/S ratio 8.97 · EPS (TTM) $0.1700 · Dividend yield 13.1% · Net margin 22.5% · Return on equity 11.6% · Return on assets (EBIT) 8.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 74% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 10%, WXIBF screens cheaper than that median.
Fair Value models
Bear $4.88
Fair Value $7.45
Bull $13.75
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.1285 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$2.11
$3.13
$6.37
74
EPV
$2.06
$2.34
$2.60
74
Growth DCF
$2.00
$3.65
$6.34
73
All 24 models by family
DCF Models
FCF DCF
$2.11
$3.13
$6.37
74
Owner Earnings
$2.04
$4.22
$8.79
69
5Y Revenue Exit
$2.13
$3.55
$6.55
67
5Y EBITDA Exit
$3.17
$5.66
$10.56
69
5Y P/E Exit
$2.98
$6.56
$11.49
65
10Y Revenue Exit
$2.08
$4.44
$6.01
64
10Y EBITDA Exit
$2.92
$6.68
$13.44
61
10Y P/E Exit
$2.78
$6.28
$12.15
58
Earnings-Based
Graham-Dodd
$1.18
$8.24
$11.56
61
Lynch FV
$4.26
$6.08
$7.91
59
PEG = 1.0
$4.26
$6.08
$7.91
55
EPV
$2.06
$2.34
$2.60
74
Multiples
P/E Multiple
$2.87
$3.82
$4.78
63
P/S Multiple
$2.02
$2.70
$3.37
58
P/B Multiple
$2.22
$2.95
$3.69
55
EV/EBIT
$3.33
$4.33
$5.33
66
EV/EBITDA
$3.45
$4.49
$5.52
67
EV/Revenue
$1.95
$2.64
$3.34
54
Asset-Based
NCAV (Graham)
$0.8600
$1.15
$1.72
54
Growth DCF
Growth DCF
$2.00
$3.65
$6.34
73
Rev-Margin DCF
$2.32
$4.01
$7.55
67
Economic Profit
Residual Income
$1.51
$1.69
$2.22
68
ROIC Compounder
$2.47
$3.36
$4.18
70
Growth Earnings
Growth-Adj P/E
$5.65
$8.07
$10.49
65
Notify me when WXIBF reaches fair value
Put WXIBF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
68/100
Of which business quality 66 · Market factors (momentum, volatility) 77
Profitability
47
Margins and returns on capital today
Quality Growth
74
Are margins and returns improving?
Cashflow
58
Earnings quality: real cash, not paper profit
Fin. Strength
83
Balance sheet, leverage, solvency risk
Investment
40
Disciplined investing over empire-building
Low Volatility
53
Calm price path (market factor)
Momentum
80
Price trend over the last 3–12 months (market factor)
52W Momentum
100
Distance to the 52-week high (market factor)
Net Issuance
95
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+13.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.5%
Start year 2020 (pandemic). Over 10 years: +43.9% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+45.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+36.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+23.3%
Dividend (yield on the price)13.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.23.3% vs 56.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.27% → 31%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+26.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+15.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +24.2% a year for the price and +13.4% for the forecasts.
Forecast 2026 (sales)+18.8%
Forecast 2027 (sales)+17.3%
Projected 2028 (sales)+15.4%
Projected 2029 (sales)+13.5%
Projected 2030 (sales)+11.6%
Watch WXIBF, get fair value alerts →
Recent news
News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.
Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
- WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability
- WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership
- WuXi Biologics Reports Strong Profitable Growth in H1 2026
- Is WuXi Biologics (Cayman) (SEHK:2269) Still Below Fair Value On FTSE4Good Recognition?
Compare WuXi Biologics (Cayman) Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 576 stocks
Beats the industry median on 11/12 measures
Overall it ranks above its industry peers.
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $527.67 | $580.44 | +10% |
| Regeneron Pharmaceuticals, Inc REGN | $752.25 | $1,275 | +69% |
| argenx SE ARGX | $959.49 | $918.60 | −4% |
| CSL Limited CSL | A$175.35 | A$192.89 | +10% |
| Samsung Biologics Co 207940 | 1,354,000 KRW | 1,489,400 KRW | +10% |
| BeOne Medicines AG ONC | $360.85 | $280.94 | −22% |
| Alnylam Pharmaceuticals, Inc ALNY | $255.96 | $217.88 | −15% |
| Royalty Pharma plc RPRX | $58.21 | $19.01 | −67% |
| Celltrion, Inc 068270 | 177,400 KRW | 74,519 KRW | −58% |
| Incyte Corporation INCY | $124.82 | $201.35 | +61% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is WuXi Biologics (Cayman) Inc (WXIBF) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $7.45 versus a price of $6.77, about +10% upside (undervalued).
What is the fair value of WXIBF?
Our model-based fair value for WuXi Biologics (Cayman) Inc is $7.45 (as of Oct 3, 2026), built from audited fundamentals. The current price: $6.77.
What is the quality score of WXIBF?
WuXi Biologics (Cayman) Inc has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for WuXi Biologics (Cayman) Inc (WXIBF)?
Our model-based price target is the fair value of $7.45 (as of Oct 3, 2026) from 24 valuation models. Cautious scenario $4.88, optimistic scenario $13.75. It is a calculation from audited fundamentals, not an analyst target.
What is the WuXi Biologics (Cayman) Inc stock forecast for 2026?
Our models put fair value at $7.45, about +10% upside versus a price of $6.77 (undervalued). Cautious scenario $4.88, optimistic scenario $13.75. The calculation is refreshed regularly with new filings.
What is the revenue of WuXi Biologics (Cayman) Inc (WXIBF)?
WuXi Biologics (Cayman) Inc reported trailing-twelve-month revenue of about 21.8B CNY (latest available figure, as of Oct 3, 2026).
Does WuXi Biologics (Cayman) Inc pay a dividend?
WuXi Biologics (Cayman) Inc currently shows a dividend yield of about 13.14% relative to its recent price (as of Oct 3, 2026).
What growth is priced into WuXi Biologics (Cayman) Inc (WXIBF)?
For today's price to be fair in a discounted-cash-flow model, WuXi Biologics (Cayman) Inc would have to grow free cash flow by +26.3 % per year for five years (discount rate 8.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +30.5 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of WXIBF use?
Our models discount WuXi Biologics (Cayman) Inc at 8.2 %: a base by market capitalisation (large), damped by beta 0.56, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For WuXi Biologics (Cayman) Inc that is +26.3 % per year a year over ten years, using the same discount rate (8.2 %) and the same formula as our fair value.
How much growth has WuXi Biologics (Cayman) Inc (WXIBF) delivered so far?
Over the past 5 years revenue at WuXi Biologics (Cayman) Inc grew +30.5 % a year. The price currently implies +26.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of WuXi Biologics (Cayman) Inc (WXIBF) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into WuXi Biologics (Cayman) Inc (+26.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of WuXi Biologics (Cayman) Inc (WXIBF)?
The free-cash-flow yield on the price is 1.48 %: that much free cash flow WuXi Biologics (Cayman) Inc produces per unit of market value. When it exceeds the discount rate of our models (8.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of WuXi Biologics (Cayman) Inc (WXIBF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For WuXi Biologics (Cayman) Inc it is $7.45 per share (as of Oct 3, 2026), against a price of $6.77. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is WuXi Biologics (Cayman) Inc stock overvalued or undervalued in 2026?
As of Oct 3, 2026, WXIBF trades below its calculated fair value: price $6.77, fair value $7.45, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of WXIBF?
No. The price is what the market pays today ($6.77); the fair value is what the company's own numbers justify ($7.45). For WuXi Biologics (Cayman) Inc the two are $0.6770 per share apart. That gap is exactly why we show both numbers side by side.
How much is WuXi Biologics (Cayman) Inc worth?
The market values WuXi Biologics (Cayman) Inc at about $28.3B (market capitalisation, as of Oct 3, 2026). Per share that is $6.77; our models calculate a fair value of $7.45 per share.
What do the bullish and bearish scenarios say about WXIBF?
Our models span a range for WuXi Biologics (Cayman) Inc: cautious scenario $4.88, base $7.45, optimistic $13.75 per share (as of Oct 3, 2026, price $6.77). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of WXIBF?
WuXi Biologics (Cayman) Inc trades at a price-to-earnings ratio of 39.8 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $7.45 is built from several models across several years. Other multiples: PEG 1.1.
What is the PEG ratio of WXIBF?
The PEG ratio of WuXi Biologics (Cayman) Inc is 1.09 (P/E divided by earnings growth, as of Oct 3, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of WuXi Biologics (Cayman) Inc (WXIBF)?
Balance-sheet figures for WuXi Biologics (Cayman) Inc (as of Oct 3, 2026): return on equity 11.6%, debt of 0.00 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is WXIBF from its 52-week high?
WuXi Biologics (Cayman) Inc trades at $6.77, at its 52-week high of $6.77 and 74% above the low of $3.90 (as of Sep 28, 2026). Distance from the high says nothing about value: that is what the fair value of $7.45 is for.
Which stocks are comparable to WuXi Biologics (Cayman) Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is WuXi Biologics (Cayman) Inc stock attractive at the current price?
The data as of Oct 3, 2026: price $6.77, calculated fair value $7.45 (+10%), Quality Score 68/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of WXIBF calculated?
We run WuXi Biologics (Cayman) Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $7.45, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. WuXi Biologics (Cayman) Inc currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of WuXi Biologics (Cayman) Inc (WXIBF)?
The closing price on Sep 28, 2026 was $6.77. Our model-based fair value is $7.45, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with WuXi Biologics (Cayman) Inc right now?
The model range is unusually wide ($4.88 to $13.75). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of WuXi Biologics (Cayman) Inc (WXIBF) come from?
Earnings per share at WuXi Biologics (Cayman) Inc grew +50.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +42.5 %, EBIT margin +5.8 %, tax rate +0.2 %, residual (interest, one-offs) +0.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of WuXi Biologics (Cayman) Inc
How large is the market capitalisation of WuXi Biologics (Cayman) Inc (WXIBF)?
The market capitalisation of WuXi Biologics (Cayman) Inc is $28.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of WuXi Biologics (Cayman) Inc (WXIBF)?
The price-to-sales ratio of WuXi Biologics (Cayman) Inc is 8.97 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of WuXi Biologics (Cayman) Inc (WXIBF)?
Earnings per share at WuXi Biologics (Cayman) Inc are $0.1700 (price ÷ EPS = P/E 39.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of WuXi Biologics (Cayman) Inc (WXIBF)?
The dividend yield of WuXi Biologics (Cayman) Inc is 13.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of WuXi Biologics (Cayman) Inc (WXIBF)?
The net margin of WuXi Biologics (Cayman) Inc is 22.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of WuXi Biologics (Cayman) Inc (WXIBF)?
The return on equity (ROE) of WuXi Biologics (Cayman) Inc is 11.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of WuXi Biologics (Cayman) Inc (WXIBF)?
On an EBIT basis the return on assets of WuXi Biologics (Cayman) Inc is 8.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of WuXi Biologics (Cayman) Inc (WXIBF)?
The operating margin of WuXi Biologics (Cayman) Inc is 33.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at WuXi Biologics (Cayman) Inc (WXIBF)?
Revenue at WuXi Biologics (Cayman) Inc is growing +17.2% versus a year earlier (3y avg +11.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at WuXi Biologics (Cayman) Inc (WXIBF)?
Earnings per share at WuXi Biologics (Cayman) Inc are growing +39.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does WuXi Biologics (Cayman) Inc (WXIBF) hold?
WuXi Biologics (Cayman) Inc holds more cash than debt, 6.1B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch WuXi Biologics (Cayman) Inc in the live analysis
One click puts WuXi Biologics (Cayman) Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.